@article{beca04c7de2248918c48fdba4bd3f257,
title = "Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring",
keywords = "Non-small cell lung cancer, Tyrosine kinase inhibitor, QT interval, Disease flare, Drug monitoring, CELL LUNG-CANCER, 1ST-LINE TREATMENT, PHASE-3 TRIAL, OPEN-LABEL, GEFITINIB, ADENOCARCINOMA, DACOMITINIB, INHIBITOR, ERLOTINIB, INTERVAL",
author = "Mart Schiefer and Hendriks, {Lizza E. L.} and Dinh Dinh and Ulrich Lalji and Dingemans, {Anne-Marie C.}",
year = "2018",
month = mar,
day = "1",
doi = "10.1016/j.ejca.2017.12.011",
language = "English",
volume = "91",
pages = "92--98",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "ELSEVIER SCI LTD",
}